Astellas Pharma Inc. ALPMF OTC

Astellas Pharma Inc. (ALPMF) has shown strong revenue growth over the past 3 years, expanding from $1.30T to $1.91T (average +14%/yr). Net income reached $50.7B, reflecting exceptional earnings expansion at +31.5%/yr on average. The net profit margin is 2.7%, which is thin. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 81.7% (high), with a +1.2pp trend over the period. With a $30B market cap and MOAT composite score of 84/100, the company has a strong competitive position.

Criteria proven by this page:

• GROWTH (90/100, Pass) — proving strong growth momentum
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 22-year history, the company was profitable in 22 of 22 years — a perfect long-term track record
• INCOME (30/100, Partial) — the company is profitable but margin is below 15%
• MOAT (84/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 73/100 with 4/6 criteria passed.